NASDAQ:DRUG

Bright Minds Biosciences Up After $220 Piper Sandler Call—Key Level for DRUG Traders
····

Bright Minds Biosciences Up After $220 Piper Sandler Call—Key Level for DRUG Traders

Bright Minds Biosciences shares jumped 11.1% to $82.78 after Piper Sandler raised its price target to $220 and reiterated an “Overweight” rating. The company reported C$309.7 million in cash at March 31, up from C$82.9 million in September, and a wider net loss. Lead drug BMB-101 completed Phase 1 and reported Phase 2 data for epilepsy and absence seizures.
May 21, 2026

Stock Market Today

  • 6 Key Numbers to Value Pro Medicus Ltd (ASX:PME) Shares
    May 30, 2026, 1:15 AM EDT. Pro Medicus Ltd (ASX:PME), a radiology IT software provider, has seen its share price fall 40.59% since the start of the year. The company posted $162 million in annual revenue with a 33.4% compound annual growth rate over three years. Its gross margin of 99.8% highlights operational strength. PME reported a profit of $83 million last year, growing at 39.0% CAGR over three years. Financial health is robust, with net debt of negative $153 million, indicating more cash than debt, and a low debt-to-equity ratio of 1.1%. The return on equity (ROE) stands at 50.7%, reflecting efficient capital use. These metrics provide key insights to evaluate PME's share performance this year amid market volatility.